Sector

ITHRIV includes the University of Virginia, Inova Health System, Virginia Tech and Carilion Clinic as partners, with the Center for Open Science and UVA’s Licensing & Ventures Group as affiliates. The focus of iTHRIV is “using data to improve health” and leverages the data science expertise across the state.

The University of Virginia Health System is expanding its telehealth capacity to help patients across Virginia better prevent or manage chronic conditions that include diabetes, prediabetes, and heart disease.

University of Virginia School of Medicine professor Lee Ritterband created SHUTi (Sleep Healthy Using the Internet) – a digital therapeutic that uses cutting-edge technology to administer cognitive behavioral therapy for people suffering from insomnia. Ritterband's goal is to increase access to effective and affordable behavioral health care

A new program will use telehealth to bring together a University of Virginia Health System team with primary care providers in the Appalachian region of Virginia to improve lung disease prevention, diagnosis and treatment.

Local biotechnology industry leader Nikki Hastings, PhD, has been named the first Executive Director of the CvilleBioHub, a non-profit that connects and supports the Charlottesville-area biotechnology sector.  CvilleBioHub will receive strategic planning assistance from Denise Hubbard, program director for UVA’s Office of Economic Development, and Grant Tate, of the Bridge Ltd. consulting firm.

The UVA Licensing & Ventures Group helps discoveries reach their full potential in the marketplace. In 2018 there were 213 invention disclosures filed, 59 U.S. patents issued and 77 transactions with commercial partners. 

UVA Professor Shawn Russell helps those with disabilities take on skiing, proving that biomechanics research has real-life applications that can change lives for the better in Virginia and beyond.

The UVA Center for Engineering in Medicine promotes innovation by embedding engineering students into clinical environments and nursing and medical trainees into engineering laboratories. Students work in multidisciplinary teams to acquire the necessary technical vocabulary, cultural literacy, and experience for careers in health care innovation.

A WMRA podcast alludes to UVA's role in the biotechnology industry in Central Virginia. Grounded in UVA research and support from UVA's Licensing and Ventures Group (LVG), companies like Contraline and TearSolutions are making exciting advances and nurturing the biotechnology ecosystem in the region.

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG). Now, LVG has exited from TypeZero following acquisition by DexCom, the leader in continuous glucose monitoring for diabetes. The news highlights UVA's cultivation of research and entrepreneurship that ultimately improves lives and stimulates our economy.

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc. all have the potential to make an impact and to drive the local and regional economy. The LVG Seed Fund offers UVA-affiliated startups capital to advance opportunities often considered too early for investment by traditional sources.

UVA's Center for Applied Biomechanics is taking a leadership role in analyzing populations with heightened vulnerability to traffic-related injury or death, specifically women and obese passengers. Increased understanding of injury tolerance and prediction will allow automotive manufacturers, policymakers, and researchers to make vehicles safer for the entire population.